Short-term treatment with monoclonal anti-tumor necrosis factor-α antibody in refractory long-standing rheumatoid arthritis.

被引：0
|
作者：
Fantini, F
Sinigaglia, L
Zeni, S
Cagnoli, M
Favalli, EG
Colombelli, P
机构：
来源：
ARTHRITIS AND RHEUMATISM | 2000年 / 43卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
964
引用
收藏
页码：S227 / S227
页数：1
相关论文
共 50 条
  • [31] Effectiveness of Anti-Tumor Necrosis Factor-α Agents in the Treatment of Refractory Juvenile Dermatomyositis
    Boulter, E. L.
    Beard, L.
    Ryder, Clive
    Pilkington, Clarissa
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S795 - S795
  • [32] Therapeutic effects of the anti-tumor necrosis factor monoclonal antibody, infliximab, in four children with refractory juvenile idiopathic arthritis
    Norambuena, X.
    Mallol, J.
    Rios, G.
    Quevedo, F.
    Quezada, A.
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2007, 35 (02) : 52 - 56
  • [33] Effects of anti-tumor necrosis factor (TNF) therapy and methotrexate on bone density in rheumatoid arthritis.
    Coulson, Kathryn
    Pepmueller, Peri
    Hinkle, Kim
    Kremer, Joel
    Reed, George
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S79 - S80
  • [34] Anti-tumor necrosis factor therapy with infliximab decreases the risk of stroke in patients with rheumatoid arthritis.
    Wolfe, F
    Nadareishvili, ZG
    Hallenbeck, JM
    Michaud, K
    ARTHRITIS AND RHEUMATISM, 2004, 50 (12): : 4099 - 4099
  • [35] The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis
    Haraoui, B
    JOURNAL OF RHEUMATOLOGY, 2005, 32 : 46 - 47
  • [36] Tumor necrosis factor-α blockade in the treatment of rheumatoid arthritis
    Keystone, EC
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2001, 27 (02) : 427 - 443
  • [37] Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-α antibody therapy
    Sekigawa, I.
    Yanagida, M.
    Iwabuchi, K.
    Kaneda, K.
    Kaneko, H.
    Takasaki, Y.
    Jung, G.
    Sone, S.
    Tanaka, Y.
    Ogawa, H.
    Takamori, K.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (02) : 261 - 267
  • [38] Appearance of rheumatoid nodules following anti-tumor necrosis factor a treatment with adalimumab for rheumatoid arthritis
    Scrivo, R.
    Spadaro, A.
    Iagnocco, A.
    Valesini, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (01) : 117 - 117
  • [39] Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
    Weinblatt, ME
    Keystone, EC
    Furst, DE
    Moreland, LW
    Weisman, MH
    Birbara, CA
    Teoh, LA
    Fischkoff, SA
    Chartash, EK
    ARTHRITIS AND RHEUMATISM, 2003, 48 (01): : 35 - 45
  • [40] Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis
    Sugiyama, Masafumi
    Okuda, Saki
    Hirooka, Yasuaki
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2022, 6 (01)
12345